Share this article
TEL AVIV, Israel and LAUSANNE, Switzerland, Jan. 14, 2021 /PRNewswire/
Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to leverage Nucleai s artificial intelligence (AI) -powered biomarker research & discovery platform for one of Debiopharm s clinical stage oncology assets.
Having become one of Debiopharm s investment portfolio companies in 2020 (Series A), Nucleai s pathology-based platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system s spatial characteristics, creating unique and specific histological biomarkers that can predict patient response. These biomarkers allow further stratification of responder/non-responder patient populations, improve the success rate of clinical t
While COVID-19 cases in Ohio s schools increase, many educators say they re eyeing a figure that is likely exponentially larger, but not tracked statewide: students who are quarantining due to potential exposure to the virus in their districts.
Even if they don t become sick, quarantining students are forced to miss in-person classes. In a nine-week grading period, a 14-day quarantine which health officials recommended for most of the school year would result in a student missing nearly one-fourth of all classes.
In central Ohio, most districts already have reduced in-person classes to two or three days weekly. It s important for us to have kids here, even if it s just two days a week, to build those relationships, said Diane Allen, superintendent of the Marysville school district. These are trying times. We want to wrap our arms around them academically, socially and emotionally.